Maha H Hussain
Northwestern University · University Health Network Princess Margaret Cancer Center LAO · University of Chicago Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Maha H Hussain as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04033432 · sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate CancerNorthwestern University · unknown · Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents · principal investigator
- Ph1/Ph2NCT03854474 · Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaNational Cancer Institute (NCI) · active not recruiting · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 · principal investigator
- Ph2NCT01576172 · Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerNational Cancer Institute (NCI) · completed · Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7 · principal investigator
- Ph2NCT00393796 · Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial CarcinomaUniversity of Michigan Rogel Cancer Center · terminated · Bladder Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- NU-TRIHO (Northwestern University Translational Research in Hematology-Oncology) Training ProgramT32CA268935 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2023 to 2026 · $248,793 awarded in 2026Same name and institution; not confirmed by an ID
- SPORE in Prostate CancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2018 to 2025 · $1,881,134 awarded in 2025Same name and institution; not confirmed by an ID
- Developmental Research ProgramP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2014 to 2018 · $114,428 awarded in 2018Same name and institution; not confirmed by an ID
- Developmental ProjectsP50CA093990 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2008 to 2012 · $74,885 awarded in 2012Same name and institution; not confirmed by an ID
- Developmental Research ProgramP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2008 to 2012 · $66,241 awarded in 2012Same name and institution; not confirmed by an ID
- PRMSP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2006 to 2010 · $156,959 awarded in 2010Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA060553 · NCI · NORTHWESTERN UNIVERSITY · PI Aleksandar Zafirovski · fiscal years 2019 to 2026Named on NCT04033432, NCT03854474
- Clinical and Experimental TherapeuticsP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI Wendy Stock · fiscal years 2019 to 2026Named on NCT01576172
- Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)P50CA097186 · NCI · FRED HUTCHINSON CANCER CENTER · PI Martin Edwin Gleave · fiscal years 2019 to 2026Named on NCT01576172
- U01CA062491RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01576172
- U01CA070095RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01576172
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2020 to 2026Named on NCT01576172
- UM1CA186705RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01576172
- UM1CA186716RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01576172
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:07 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med · 20043,025 citationsRCR 65.3
- 372 citationsRCR 8.4
- 305 citationsRCR 6.5
- 182 citationsRCR 4.0
- 148 citationsRCR 3.3
- Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).Cancer · 2008110 citationsRCR 2.2
- Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.J Clin Oncol · 201188 citationsRCR 2.6
- 79 citationsRCR 1.8
- 74 citationsRCR 1.7
- A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).J Urol · 200969 citationsRCR 1.7